PubMed:10200007 JSONTXT

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":22,"end":50},"obj":"RNA"},{"id":"T2","span":{"begin":109,"end":126},"obj":"cell_type"},{"id":"T3","span":{"begin":195,"end":218},"obj":"protein"},{"id":"T4","span":{"begin":220,"end":222},"obj":"protein"},{"id":"T5","span":{"begin":365,"end":372},"obj":"RNA"},{"id":"T6","span":{"begin":691,"end":698},"obj":"RNA"},{"id":"T7","span":{"begin":776,"end":783},"obj":"RNA"},{"id":"T8","span":{"begin":971,"end":978},"obj":"RNA"},{"id":"T9","span":{"begin":1052,"end":1059},"obj":"RNA"},{"id":"T10","span":{"begin":1162,"end":1169},"obj":"RNA"},{"id":"T11","span":{"begin":1223,"end":1240},"obj":"cell_type"},{"id":"T12","span":{"begin":1359,"end":1366},"obj":"RNA"},{"id":"T13","span":{"begin":2033,"end":2035},"obj":"protein"}],"text":"In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma.\nBACKGROUND: In vivo regulation of the glucocorticoid receptor (GR) by glucocorticoids provides a means of modulating sensitivity of targeted cells.\nOBJECTIVE: We sought to determine the in vivo modulation of GR mRNA expression by fluticasone propionate (FP) in subjects with mild asthma.\nMETHODS: Ten atopic asthmatic subjects were treated with FP 250 microg twice daily for 4 weeks. Before and after treatment, the patients underwent fiberoptic bronchoscopy with endobronchial biopsy and sampling of venous blood for measurements of GR mRNA levels. A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortisol excretion and an adrenocorticotropic hormone test before and after treatment with FP were performed.\nRESULTS: A high interindividual variation in GR mRNA expression was seen. However, we detected a significant reduction of the GR mRNA levels in the endobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/microg RNA, respectively; P \u003c.01). In the peripheral blood lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/microg RNA, respectively; P \u003c.001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-hour urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol/L, respectively; P \u003c.01), whereas the feedback regulation of glucocorticoid synthesis by means of the hypothalamic-pituitary-adrenal axis as assessed by the adrenocorticotropic hormone test remained normal after treatment with FP.\nCONCLUSION: The results in this study confirm the potency of the inhaled corticosteroid FP and provide evidence for a considerable tissue-specific interindividual variation in the expression of the GR."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"10200007-0#22#45#gene2908","span":{"begin":22,"end":45},"obj":"gene2908"},{"id":"10200007-0#149#155#diseaseC0004096","span":{"begin":149,"end":155},"obj":"diseaseC0004096"},{"id":"10200007-10#279#306#gene5443","span":{"begin":1761,"end":1788},"obj":"gene5443"},{"id":"10200007-10#237#246#diseaseC0032002","span":{"begin":1719,"end":1728},"obj":"diseaseC0032002"}],"relations":[{"id":"22#45#gene2908149#155#diseaseC0004096","pred":"associated_with","subj":"10200007-0#22#45#gene2908","obj":"10200007-0#149#155#diseaseC0004096"},{"id":"279#306#gene5443237#246#diseaseC0032002","pred":"associated_with","subj":"10200007-10#279#306#gene5443","obj":"10200007-10#237#246#diseaseC0032002"}],"text":"In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma.\nBACKGROUND: In vivo regulation of the glucocorticoid receptor (GR) by glucocorticoids provides a means of modulating sensitivity of targeted cells.\nOBJECTIVE: We sought to determine the in vivo modulation of GR mRNA expression by fluticasone propionate (FP) in subjects with mild asthma.\nMETHODS: Ten atopic asthmatic subjects were treated with FP 250 microg twice daily for 4 weeks. Before and after treatment, the patients underwent fiberoptic bronchoscopy with endobronchial biopsy and sampling of venous blood for measurements of GR mRNA levels. A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortisol excretion and an adrenocorticotropic hormone test before and after treatment with FP were performed.\nRESULTS: A high interindividual variation in GR mRNA expression was seen. However, we detected a significant reduction of the GR mRNA levels in the endobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/microg RNA, respectively; P \u003c.01). In the peripheral blood lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/microg RNA, respectively; P \u003c.001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-hour urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol/L, respectively; P \u003c.01), whereas the feedback regulation of glucocorticoid synthesis by means of the hypothalamic-pituitary-adrenal axis as assessed by the adrenocorticotropic hormone test remained normal after treatment with FP.\nCONCLUSION: The results in this study confirm the potency of the inhaled corticosteroid FP and provide evidence for a considerable tissue-specific interindividual variation in the expression of the GR."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":156},"obj":"Sentence"},{"id":"S2","span":{"begin":157,"end":304},"obj":"Sentence"},{"id":"S3","span":{"begin":305,"end":444},"obj":"Sentence"},{"id":"S4","span":{"begin":445,"end":540},"obj":"Sentence"},{"id":"S5","span":{"begin":541,"end":706},"obj":"Sentence"},{"id":"S6","span":{"begin":707,"end":784},"obj":"Sentence"},{"id":"S7","span":{"begin":785,"end":925},"obj":"Sentence"},{"id":"S8","span":{"begin":926,"end":999},"obj":"Sentence"},{"id":"S9","span":{"begin":1000,"end":1204},"obj":"Sentence"},{"id":"S10","span":{"begin":1205,"end":1481},"obj":"Sentence"},{"id":"S11","span":{"begin":1482,"end":1834},"obj":"Sentence"},{"id":"S12","span":{"begin":1835,"end":2036},"obj":"Sentence"}],"text":"In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma.\nBACKGROUND: In vivo regulation of the glucocorticoid receptor (GR) by glucocorticoids provides a means of modulating sensitivity of targeted cells.\nOBJECTIVE: We sought to determine the in vivo modulation of GR mRNA expression by fluticasone propionate (FP) in subjects with mild asthma.\nMETHODS: Ten atopic asthmatic subjects were treated with FP 250 microg twice daily for 4 weeks. Before and after treatment, the patients underwent fiberoptic bronchoscopy with endobronchial biopsy and sampling of venous blood for measurements of GR mRNA levels. A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortisol excretion and an adrenocorticotropic hormone test before and after treatment with FP were performed.\nRESULTS: A high interindividual variation in GR mRNA expression was seen. However, we detected a significant reduction of the GR mRNA levels in the endobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/microg RNA, respectively; P \u003c.01). In the peripheral blood lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/microg RNA, respectively; P \u003c.001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-hour urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol/L, respectively; P \u003c.01), whereas the feedback regulation of glucocorticoid synthesis by means of the hypothalamic-pituitary-adrenal axis as assessed by the adrenocorticotropic hormone test remained normal after treatment with FP.\nCONCLUSION: The results in this study confirm the potency of the inhaled corticosteroid FP and provide evidence for a considerable tissue-specific interindividual variation in the expression of the GR."}

{"project":"genia-medco-coref","denotations":[{"id":"C1","span":{"begin":22,"end":50},"obj":"NP"},{"id":"C2","span":{"begin":130,"end":155},"obj":"NP"},{"id":"C3","span":{"begin":191,"end":223},"obj":"NP"},{"id":"C4","span":{"begin":365,"end":383},"obj":"NP"},{"id":"C5","span":{"begin":387,"end":414},"obj":"NP"},{"id":"C6","span":{"begin":418,"end":443},"obj":"NP"},{"id":"C7","span":{"begin":454,"end":483},"obj":"NP"},{"id":"C8","span":{"begin":569,"end":581},"obj":"NP"},{"id":"C9","span":{"begin":691,"end":705},"obj":"NP"},{"id":"C10","span":{"begin":776,"end":783},"obj":"NP"},{"id":"C12","span":{"begin":907,"end":909},"obj":"NP"},{"id":"C11","span":{"begin":892,"end":909},"obj":"NP"},{"id":"C13","span":{"begin":971,"end":989},"obj":"NP"},{"id":"C14","span":{"begin":1048,"end":1066},"obj":"NP"},{"id":"C15","span":{"begin":1111,"end":1123},"obj":"NP"},{"id":"C16","span":{"begin":1281,"end":1287},"obj":"NP"},{"id":"C17","span":{"begin":1291,"end":1294},"obj":"NP"},{"id":"C19","span":{"begin":1831,"end":1833},"obj":"NP"},{"id":"C18","span":{"begin":1816,"end":1833},"obj":"NP"},{"id":"C20","span":{"begin":2029,"end":2035},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-ident","subj":"C6","obj":"C2"},{"id":"R2","pred":"coref-ident","subj":"C8","obj":"C7"},{"id":"R3","pred":"coref-ident","subj":"C10","obj":"C1"},{"id":"R4","pred":"coref-ident","subj":"C12","obj":"C5"},{"id":"R5","pred":"coref-ident","subj":"C13","obj":"C4"},{"id":"R6","pred":"coref-ident","subj":"C14","obj":"C9"},{"id":"R7","pred":"coref-ident","subj":"C15","obj":"C11"},{"id":"R8","pred":"coref-ident","subj":"C16","obj":"C3"},{"id":"R9","pred":"coref-pron","subj":"C17","obj":"C16"},{"id":"R10","pred":"coref-ident","subj":"C19","obj":"C12"},{"id":"R11","pred":"coref-ident","subj":"C18","obj":"C15"},{"id":"R12","pred":"coref-ident","subj":"C20","obj":"C16"}],"text":"In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma.\nBACKGROUND: In vivo regulation of the glucocorticoid receptor (GR) by glucocorticoids provides a means of modulating sensitivity of targeted cells.\nOBJECTIVE: We sought to determine the in vivo modulation of GR mRNA expression by fluticasone propionate (FP) in subjects with mild asthma.\nMETHODS: Ten atopic asthmatic subjects were treated with FP 250 microg twice daily for 4 weeks. Before and after treatment, the patients underwent fiberoptic bronchoscopy with endobronchial biopsy and sampling of venous blood for measurements of GR mRNA levels. A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortisol excretion and an adrenocorticotropic hormone test before and after treatment with FP were performed.\nRESULTS: A high interindividual variation in GR mRNA expression was seen. However, we detected a significant reduction of the GR mRNA levels in the endobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/microg RNA, respectively; P \u003c.01). In the peripheral blood lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/microg RNA, respectively; P \u003c.001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-hour urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol/L, respectively; P \u003c.01), whereas the feedback regulation of glucocorticoid synthesis by means of the hypothalamic-pituitary-adrenal axis as assessed by the adrenocorticotropic hormone test remained normal after treatment with FP.\nCONCLUSION: The results in this study confirm the potency of the inhaled corticosteroid FP and provide evidence for a considerable tissue-specific interindividual variation in the expression of the GR."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":22,"end":45},"obj":"protein_family_or_group"},{"id":"T2","span":{"begin":88,"end":104},"obj":"tissue"},{"id":"T3","span":{"begin":109,"end":126},"obj":"cell_type"},{"id":"T4","span":{"begin":144,"end":155},"obj":"other_name"},{"id":"T5","span":{"begin":195,"end":218},"obj":"protein_family_or_group"},{"id":"T6","span":{"begin":220,"end":222},"obj":"protein_family_or_group"},{"id":"T7","span":{"begin":365,"end":372},"obj":"RNA_family_or_group"},{"id":"T8","span":{"begin":387,"end":409},"obj":"other_organic_compound"},{"id":"T9","span":{"begin":411,"end":413},"obj":"other_organic_compound"},{"id":"T10","span":{"begin":432,"end":443},"obj":"other_name"},{"id":"T11","span":{"begin":465,"end":483},"obj":"multi_cell"},{"id":"T12","span":{"begin":502,"end":504},"obj":"other_organic_compound"},{"id":"T13","span":{"begin":592,"end":615},"obj":"other_name"},{"id":"T14","span":{"begin":621,"end":641},"obj":"other_name"},{"id":"T15","span":{"begin":658,"end":670},"obj":"tissue"},{"id":"T16","span":{"begin":691,"end":698},"obj":"RNA_family_or_group"},{"id":"T17","span":{"begin":776,"end":783},"obj":"RNA_family_or_group"},{"id":"T18","span":{"begin":808,"end":815},"obj":"other_name"},{"id":"T19","span":{"begin":816,"end":824},"obj":"lipid"},{"id":"T20","span":{"begin":842,"end":869},"obj":"other_organic_compound"},{"id":"T21","span":{"begin":907,"end":909},"obj":"other_organic_compound"},{"id":"T22","span":{"begin":971,"end":973},"obj":"protein_family_or_group"},{"id":"T23","span":{"begin":1052,"end":1059},"obj":"RNA_family_or_group"},{"id":"T24","span":{"begin":1074,"end":1094},"obj":"other_name"},{"id":"T25","span":{"begin":1111,"end":1113},"obj":"other_organic_compound"},{"id":"T26","span":{"begin":1162,"end":1169},"obj":"RNA_family_or_group"},{"id":"T27","span":{"begin":1223,"end":1240},"obj":"cell_type"},{"id":"T28","span":{"begin":1359,"end":1366},"obj":"RNA_family_or_group"},{"id":"T29","span":{"begin":1438,"end":1464},"obj":"other_name"},{"id":"T30","span":{"begin":1531,"end":1538},"obj":"other_name"},{"id":"T31","span":{"begin":1539,"end":1547},"obj":"lipid"},{"id":"T32","span":{"begin":1665,"end":1689},"obj":"other_name"},{"id":"T33","span":{"begin":1761,"end":1793},"obj":"other_name"},{"id":"T34","span":{"begin":1831,"end":1833},"obj":"other_organic_compound"},{"id":"T35","span":{"begin":1908,"end":1922},"obj":"lipid"},{"id":"T36","span":{"begin":1923,"end":1925},"obj":"other_organic_compound"},{"id":"T37","span":{"begin":2033,"end":2035},"obj":"protein_family_or_group"}],"text":"In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma.\nBACKGROUND: In vivo regulation of the glucocorticoid receptor (GR) by glucocorticoids provides a means of modulating sensitivity of targeted cells.\nOBJECTIVE: We sought to determine the in vivo modulation of GR mRNA expression by fluticasone propionate (FP) in subjects with mild asthma.\nMETHODS: Ten atopic asthmatic subjects were treated with FP 250 microg twice daily for 4 weeks. Before and after treatment, the patients underwent fiberoptic bronchoscopy with endobronchial biopsy and sampling of venous blood for measurements of GR mRNA levels. A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortisol excretion and an adrenocorticotropic hormone test before and after treatment with FP were performed.\nRESULTS: A high interindividual variation in GR mRNA expression was seen. However, we detected a significant reduction of the GR mRNA levels in the endobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/microg RNA, respectively; P \u003c.01). In the peripheral blood lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/microg RNA, respectively; P \u003c.001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-hour urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol/L, respectively; P \u003c.01), whereas the feedback regulation of glucocorticoid synthesis by means of the hypothalamic-pituitary-adrenal axis as assessed by the adrenocorticotropic hormone test remained normal after treatment with FP.\nCONCLUSION: The results in this study confirm the potency of the inhaled corticosteroid FP and provide evidence for a considerable tissue-specific interindividual variation in the expression of the GR."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":22,"end":45},"obj":"gene:2908"},{"id":"T1","span":{"begin":149,"end":155},"obj":"disease:C0004096"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma.\nBACKGROUND: In vivo regulation of the glucocorticoid receptor (GR) by glucocorticoids provides a means of modulating sensitivity of targeted cells.\nOBJECTIVE: We sought to determine the in vivo modulation of GR mRNA expression by fluticasone propionate (FP) in subjects with mild asthma.\nMETHODS: Ten atopic asthmatic subjects were treated with FP 250 microg twice daily for 4 weeks. Before and after treatment, the patients underwent fiberoptic bronchoscopy with endobronchial biopsy and sampling of venous blood for measurements of GR mRNA levels. A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortisol excretion and an adrenocorticotropic hormone test before and after treatment with FP were performed.\nRESULTS: A high interindividual variation in GR mRNA expression was seen. However, we detected a significant reduction of the GR mRNA levels in the endobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/microg RNA, respectively; P \u003c.01). In the peripheral blood lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/microg RNA, respectively; P \u003c.001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-hour urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol/L, respectively; P \u003c.01), whereas the feedback regulation of glucocorticoid synthesis by means of the hypothalamic-pituitary-adrenal axis as assessed by the adrenocorticotropic hormone test remained normal after treatment with FP.\nCONCLUSION: The results in this study confirm the potency of the inhaled corticosteroid FP and provide evidence for a considerable tissue-specific interindividual variation in the expression of the GR."}